Lialda Related Published Studies
Well-designed clinical trials related to Lialda (Mesalamine)
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. [2010.04]
Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. [2010.02]
Direct comparison of two different mesalamine formulations for the induction of
remission in patients with ulcerative colitis: a double-blind, randomized study. [2010]
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. [2009.12]
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. [2009.07]
Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial. [2009.05]
Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. [2008.12]
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. [2007.01]
Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients. [2006.01]
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. [2005.11]
Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. [2005.07]
Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. [2005.04]
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. [2004.09]
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. [2004.09]
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. [2004.05.15]
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. [2003.07.24]
A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. [2003.05]
Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. [2003.03]
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. [2003.01]
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. [2002.12]
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. [2002.06]
Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. [2002.05]
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. [2000.07]
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. [2000.02]
Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. [1999.03]
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. [1998.08.06]
Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. [1998.06]
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. [1998.05]
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. [1998.01]
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. [1997.10]
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. [1997.04]
A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. [1996.07]
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. [1996.03]
Well-designed clinical trials possibly related to Lialda (Mesalamine)
Abatacept for Crohn's disease and ulcerative colitis. [2012]
Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of
ulcerative colitis compared with mesalazine: a double-blinded and randomized
study. [2012]
Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative
colitis. [2011]
Curcumin for inflammatory bowel disease: a review of human studies. [2011]
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine
for moderately active ulcerative colitis - new light on a familiar question. [2011]
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4
g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011]
Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on
moderately active ulcerative colitis. A phase III parallel-dosing study. [2011]
Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. [2010.08]
Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. [2010.07]
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. [2010.06]
Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. [2010.06]
Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. [2010.04]
Efficacy of 5-ASA in the treatment of colonic diverticular disease. [2010.02]
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. [2009.11.01]
Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. [2009.11]
Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. [2009.11]
In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. [2009.09.15]
[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease] [2009.09]
Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. [2009.08]
Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. [2009.08]
The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. [2009.07]
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. [2009.06]
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. [2009.05]
Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. [2009.03]
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. [2009.02]
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. [2009.02]
Budesonide for maintenance of remission in Crohn's disease. [2009.01.21]
Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. [2009.01]
Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. [2009]
Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. [2008.11]
Budesonide for induction of remission in Crohn's disease. [2008.07.16]
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. [2008.07]
Can 5-aminosalicylic acid suppository decrease the pain after rectal band ligation? [2008.06.14]
Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. [2008.05]
Interventions for treating lymphocytic colitis. [2008.04.16]
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. [2008.01.07]
Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-beta - an Open Long-Term Trial. [2007.12]
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. [2007.11.01]
Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. [2007.11]
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. [2007.10]
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. [2007.09]
Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]
A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. [2007.07]
Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. [2007.06.15]
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. [2007.04]
Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. [2007.03]
Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. [2007.03]
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. [2007.02]
Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases. [2007]
Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? [2007]
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. [2006.12]
[Characterization of proteinuria in patients with ulcerative colitis and therapy with aminosalicylates] [2006.10.15]
Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. [2006.10.01]
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. [2006.06.01]
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. [2006.05.15]
Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. [2006.04.01]
Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. [2006.04]
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. [2006.01]
Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study. [2005.12.07]
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. [2005.12.01]
A randomized trial of nicotine enemas for active ulcerative colitis. [2005.11]
Budesonide for induction of remission in Crohn's disease. [2005.10.19]
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. [2005.07]
|
